Form 4: Revolution Medicines Executive Stock Sale

Chief Global Commercialization Officer Anthony Mancini exercised options and sold 3,121 shares of Revolution Medicines stock.

Summary

• Anthony Mancini, Chief Global Commercialization Officer of Revolution Medicines, Inc., exercised stock options for 3,121 shares at a strike price of $33.62.
• Following the exercise, the reporting person sold the 3,121 shares in multiple transactions at weighted average prices ranging from $153.30 to $154.82.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on December 24, 2025.
• The reporting person retains beneficial ownership of 54,400 shares, including Restricted Stock Units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted under a pre-established 10b5-1 plan and represents a standard exercise of executive compensation.

Positives

• The transaction was pre-planned under a Rule 10b5-1 trading plan, indicating the sales were not based on non-public information.
• The executive maintains a significant equity stake of 54,400 shares in the company.

Negatives

• The executive reduced their direct holdings through the sale of 3,121 shares.

Risks

• Future share price volatility may impact the value of the remaining equity held by the executive.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling under 10b5-1 plans is a standard practice for executives to manage personal liquidity and is generally viewed as neutral by the market.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for corporate insiders to conduct orderly divestments while avoiding potential insider trading allegations.

Stakeholder Impact

• Minimal impact expected as the transaction was pre-planned and represents a small portion of the executive's total holdings.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Revolution Medicines, RVMD, Insider Trading, Form 4, Stock Options, 10b5-1